Recursion director Hershberg sells 25,000 shares

Q: How many shares did RXRX director Robert Hershberg sell, and at what price?

Robert Hershberg sold 25,000 shares at $5.00 per share on October 6, 2026.

After the exercise, Hershberg's reported option position covered 500,000 shares and had a March 19, 2030 expiration date.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. director Robert Hershberg exercised options covering 25,000 Class A common shares at $2.22 per share on October 6, 2026, acquired those shares, and sold 25,000 shares at $5.00 per share that day. The acquisition was pursuant to a Rule 10b5-1 trading plan adopted December 17, 2025. After the exercise, his reported option position covered 500,000 shares, with a $2.22 exercise price and a March 19, 2030 expiration date.

Insider Trade Summary 10b5-1

Exercise and Sale: 25,000 shares ($70K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider HERSHBERG ROBERT

Role Director

Sold 25,000 shs ($125K)

Approx. gross sale proceeds $125K

Approx. exercise cost $56K

Approx. pre-tax spread $70K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^F2	25,000	$2.22	$56K
Exercise	Class A Common Stock ^F1	25,000	$2.22	$56K
Sale	Class A Common Stock	25,000	$5.00	$125K

Holdings After Transaction: Stock Option (Right to Buy) — 500,000 contracts (Direct); Class A Common Stock — 162,156 shares (Direct)

Footnotes (2)

F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2025.
F2. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 16, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Date exercisable varies by tranche.

Key Figures

Shares acquired upon option exercise: 25,000 shares Exercise price: $2.22 per share Shares sold: 25,000 shares +3 more

6 metrics

Shares acquired upon option exercise 25,000 shares October 6, 2026

Exercise price $2.22 per share Options exercised October 6, 2026

Shares sold 25,000 shares October 6, 2026

Sale price $5.00 per share October 6, 2026

Options covering shares after exercise 500,000 shares Reported position following the October 6, 2026 exercise

Option expiration date March 19, 2030 Options covering Class A common stock

Key Terms

Stock Option (Right to Buy), Rule 10b5-1 trading plan, Vesting Commencement Date

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Vesting Commencement Date financial

"or the Vesting Commencement Date"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did RXRX director Robert Hershberg sell, and at what price?

Robert Hershberg sold 25,000 shares at $5.00 per share on October 6, 2026.

How many RXRX shares were covered by Robert Hershberg's options after the exercise?

After exercising options covering 25,000 shares on October 6, 2026, Robert Hershberg's reported option position covered 500,000 shares, with a $2.22 exercise price and a March 19, 2030 expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/07/2026 - 06:08 PM Accepted by SEC EDGAR 10/07/2026 - 06:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HERSHBERG ROBERT

(Last)

(First)

(Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

UTAH

84101

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	10/06/2026		M⁽¹⁾		25,000	A	$2.22	187,156	D
Class A Common Stock	10/06/2026		S		25,000	D	$5	162,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.22	10/06/2026		M			25,000	⁽²⁾	03/19/2030	Class A Common Stock	25,000	$2.22	500,000	D

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2025.

2. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 16, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Date exercisable varies by tranche.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR